Latest Articles

Publication Date
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - The Malaysian Reserve

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer The Malaysian Reserve

Published: Dec. 5, 2024, 3:36 p.m.
Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - Canada NewsWire

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer Canada NewsWire

Published: Dec. 5, 2024, 2:43 p.m.
Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” - Oncology News Central

Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” Oncology News Central

Published: Dec. 5, 2024, 12:54 p.m.
Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” - oncologynewscentral.com

Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” oncologynewscentral.com

Published: Dec. 5, 2024, 12:54 p.m.
Single-Cell RNA Sequencing of PBMCs Identified Junction Plakoglobin (JUP) as Stratification Biomarker for Endometriosis.

This study aimed to identify unique characteristics in the peripheral blood mononuclear cells (PBMCs) of endometriosis patients and develop a non-invasive early diagnostic tool. Using single-cell RNA sequencing (scRNA-seq), we …

Published: Dec. 5, 2024, midnight
How to deal with anxiety after cancer treatment - The Australian Women's Weekly

How to deal with anxiety after cancer treatment The Australian Women's Weekly

Published: Dec. 4, 2024, 11:17 p.m.
Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update comes in li - Defense World

Karyopharm Therapeutics Provides Regulatory Update on Endometrial Cancer ProgramOn December 3, 2024, Karyopharm Therapeutics Inc. released a press statement outlining a regulatory update on its endometrial cancer program. This update …

Published: Dec. 4, 2024, 8:10 a.m.
NMPA greenlights new endometrial cancer therapy - Investing.com India

NMPA greenlights new endometrial cancer therapy Investing.com India

Published: Dec. 4, 2024, 1:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News - StockTitan

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News StockTitan

Published: Dec. 4, 2024, 12:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News - StockTitan

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News StockTitan

Published: Dec. 4, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!